Evidence map›Paper›PMID 40734776›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Su Yee Win, Pinunta Nittayacharn, Jatupoom Ngernmark, Mongkol Chavalitsarot, Chitinart Thedrattanawong, Khanit Sa-Ngiamsuntorn, Suradej Hongeng, Norased Nasongkla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Su Yee Win *Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Pinunta Nittayacharn *Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Jatupoom NgernmarkDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Mongkol ChavalitsarotDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Chitinart ThedrattanawongDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Khanit Sa-NgiamsuntornDepartment of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Suradej HongengDepartment of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Norased NasongklaDepartment of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell encapsulation in biocompatible microbeads offers a promising strategy for cell-based therapy in acute liver failure (ALF). This study evaluates the use of immortalized hepatocyte cells (imHCs) encapsulated in click-arginyl glycyl aspartic acid (click-RGD)-modified alginate microbeads, focusing on their biocompatibility and therapeutic potential.

Indexed as

acute liver failurecell encapsulationclick-RGD microbeadsimmortalized hepatocytesin vivo

Identifiers

PMID40734776
PMCPMC12303912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.